狄诺塞麦推荐使用量多少？

(Xgeva) was first approved in the United States in 2010 for the prevention of bone-related events in adults with bone metastases from solid tumors. It was also approved in Europe in 2011 for the same indication. As medical research advances, the U.S. Food and Drug Administration has approved an expanded use of denosumab to treat giant cell tumor of bone (GCTB) in adults and certain adolescents, making it the first drug to treat this rare disease in the United States. To this end, denosumab will provide a much-needed treatment option for patients who are inoperable or who would otherwise have to undergo extensive, life-altering surgery.

What is the recommended dosage of denosumab?

Denosumab (Xgeva) can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion, or intradermal injection. Solid tumor bone metastases: 120 mg administered subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Malignant hypercalcemia: 120 mg subcutaneously every 4 weeks, followed by a further 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Hypocalcemia must be corrected before starting treatment with this product. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels (such as phosphorus and magnesium) is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to these patients. For patients who develop serious infections while using Xgeva, physicians should evaluate the need to continue treatment with this product.